OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Histone deacetylases inhibitors as new potential drugs against Leishmania braziliensis, the main causative agent of new world tegumentary leishmaniasis
Luciana Ângelo de Souza, Matheus S. Bastos, Joice de Melo Agripino, et al.
Biochemical Pharmacology (2020) Vol. 180, pp. 114191-114191
Closed Access | Times Cited: 10
Luciana Ângelo de Souza, Matheus S. Bastos, Joice de Melo Agripino, et al.
Biochemical Pharmacology (2020) Vol. 180, pp. 114191-114191
Closed Access | Times Cited: 10
Showing 10 citing articles:
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Mengjiao Zhou, Minjian Yuan, Meng Zhang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113825-113825
Open Access | Times Cited: 56
Mengjiao Zhou, Minjian Yuan, Meng Zhang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113825-113825
Open Access | Times Cited: 56
The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance
Juliana Almeida‐Silva, Diego Menezes, Juan Mateus Pereira Fernandes, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 16
Juliana Almeida‐Silva, Diego Menezes, Juan Mateus Pereira Fernandes, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 16
Drug Discovery for Cutaneous Leishmaniasis: A Review of Developments in the Past 15 Years
Hannah N. Corman, Case W. McNamara, Malina A. Bakowski
Microorganisms (2023) Vol. 11, Iss. 12, pp. 2845-2845
Open Access | Times Cited: 10
Hannah N. Corman, Case W. McNamara, Malina A. Bakowski
Microorganisms (2023) Vol. 11, Iss. 12, pp. 2845-2845
Open Access | Times Cited: 10
Metalloenzyme Inhibitors against Zoonotic Infections: Focus on Leishmania and Schistosoma
Sara Rossi, Valeria Tudino, Gabriele Carullo, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 5, pp. 1520-1535
Closed Access | Times Cited: 3
Sara Rossi, Valeria Tudino, Gabriele Carullo, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 5, pp. 1520-1535
Closed Access | Times Cited: 3
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
Ehab Ghazy, Mohamed Abdelsalam, Dina Robaa, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 1, pp. 80-80
Open Access | Times Cited: 15
Ehab Ghazy, Mohamed Abdelsalam, Dina Robaa, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 1, pp. 80-80
Open Access | Times Cited: 15
Annatto Oil Loaded Nanostructured Lipid Carriers: A Potential New Treatment for Cutaneous Leishmaniasis
Marianna Araújo Ferreira, Renato Ferreira de Almeida Júnior, Thiago Souza Onofre, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1912-1912
Open Access | Times Cited: 13
Marianna Araújo Ferreira, Renato Ferreira de Almeida Júnior, Thiago Souza Onofre, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1912-1912
Open Access | Times Cited: 13
In vitro evaluation of Resveratrol as a potential pre-exposure prophylactic drug against Trypanosoma cruzi infection
Matías Exequiel Rodríguez, Valeria Tekiel, Vanina A. Campo
International Journal for Parasitology Drugs and Drug Resistance (2022) Vol. 20, pp. 54-64
Open Access | Times Cited: 8
Matías Exequiel Rodríguez, Valeria Tekiel, Vanina A. Campo
International Journal for Parasitology Drugs and Drug Resistance (2022) Vol. 20, pp. 54-64
Open Access | Times Cited: 8
Meroterpenoids from Gongolaria abies-marina against Kinetoplastids: In Vitro Activity and Programmed Cell Death Study
Desirée San Nicolás-Hernández, Rubén L. Rodríguez-Expósito, Atteneri López‐Arencibia, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 476-476
Open Access | Times Cited: 3
Desirée San Nicolás-Hernández, Rubén L. Rodríguez-Expósito, Atteneri López‐Arencibia, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 476-476
Open Access | Times Cited: 3
Advances in Protozoan Epigenetic Targets and Their Inhibitors for the Development of New Potential Drugs
C. Gaona, Lenci K. Vázquez‐Jiménez, Alonzo González‐González, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 543-543
Open Access | Times Cited: 3
C. Gaona, Lenci K. Vázquez‐Jiménez, Alonzo González‐González, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 543-543
Open Access | Times Cited: 3
Exploring host epigenetic enzymes as targeted therapies for visceral leishmaniasis: in silico design and in vitro efficacy of KDM6B and ASH1L inhibitors
Mukul Dutta, Tooba Qamar, Unnati Kushavah, et al.
Molecular Diversity (2024)
Closed Access
Mukul Dutta, Tooba Qamar, Unnati Kushavah, et al.
Molecular Diversity (2024)
Closed Access
